BACKGROUND AND OBJECTIVES: Anti-thymocyte globulin (ATG) is given in various conditioning regimens for children and young adults undergoing hematopoietic stem cell transplantation (HSCT) from HLA non-identical donors in order to reduce the risks of graft-versus-host disease (GvHD) and rejection after the transplant. The aim of this study was to define the effect of in vitro T-cell depletion in addition to ATG on the reconstitution of T-cell-mediated immunity. DESIGN AND METHODS: We retrospectively analyzed the engraftment kinetics and clinical performance of 134 patients (median age 5.80 years) who received ATG during myeloablative or reduced intensity conditioning, and either in vitro T-cell-depleted or unmanipulated grafts. RESULTS: T-cell reconstitution was significantly delayed after T-cell-depleted grafts, irrespectively of the conditioning intensity (p<0.001). The incidence of fatal viral and fungal infections was higher in recipients of T-cell-depleted grafts than in those receiving unmanipulated grafts (26.6-29% versus <or=13%). The rejection rate was likewise higher in recipients of T-cell-depleted grafts whether following myeloablative or reduced intensity conditioning (37% and 18%, associated with recipient chimerism or non-engraftment, respectively) versus <or=4% without graft T-cell depletion. Grades 3 and 4 acute GvHD (CI+/-SE <or=0.11+/-0.03) and severe Epstein-Barr virus lymphoproliferative disease (1.49% fatal) were rare. INTERPRETATION AND CONCLUSIONS: A combination of ex vivo and in vivo T-cell depletion, although inhibiting GvHD, prolongs the interval of T cell deficiency after HSCT and favors rejection and infections, implying that the requirement for this type of extensive T-cell depletion should be carefully re-evaluated.
BACKGROUND AND OBJECTIVES: Anti-thymocyte globulin (ATG) is given in various conditioning regimens for children and young adults undergoing hematopoietic stem cell transplantation (HSCT) from HLA non-identical donors in order to reduce the risks of graft-versus-host disease (GvHD) and rejection after the transplant. The aim of this study was to define the effect of in vitro T-cell depletion in addition to ATG on the reconstitution of T-cell-mediated immunity. DESIGN AND METHODS: We retrospectively analyzed the engraftment kinetics and clinical performance of 134 patients (median age 5.80 years) who received ATG during myeloablative or reduced intensity conditioning, and either in vitro T-cell-depleted or unmanipulated grafts. RESULTS: T-cell reconstitution was significantly delayed after T-cell-depleted grafts, irrespectively of the conditioning intensity (p<0.001). The incidence of fatal viral and fungal infections was higher in recipients of T-cell-depleted grafts than in those receiving unmanipulated grafts (26.6-29% versus <or=13%). The rejection rate was likewise higher in recipients of T-cell-depleted grafts whether following myeloablative or reduced intensity conditioning (37% and 18%, associated with recipient chimerism or non-engraftment, respectively) versus <or=4% without graft T-cell depletion. Grades 3 and 4 acute GvHD (CI+/-SE <or=0.11+/-0.03) and severe Epstein-Barr virus lymphoproliferative disease (1.49% fatal) were rare. INTERPRETATION AND CONCLUSIONS: A combination of ex vivo and in vivo T-cell depletion, although inhibiting GvHD, prolongs the interval of T cell deficiency after HSCT and favors rejection and infections, implying that the requirement for this type of extensive T-cell depletion should be carefully re-evaluated.
Authors: R F Olsson; B R Logan; S Chaudhury; X Zhu; G Akpek; B J Bolwell; C N Bredeson; C C Dvorak; V Gupta; V T Ho; H M Lazarus; D I Marks; O T H Ringdén; M C Pasquini; J R Schriber; K R Cooke Journal: Leukemia Date: 2015-03-16 Impact factor: 11.528
Authors: Matthew J Parker; Song Xue; John J Alexander; Clive H Wasserfall; Martha L Campbell-Thompson; Manuela Battaglia; Silvia Gregori; Clayton E Mathews; Sihong Song; Misty Troutt; Scott Eisenbeis; John Williams; Desmond A Schatz; Michael J Haller; Mark A Atkinson Journal: Diabetes Date: 2009-07-23 Impact factor: 9.461
Authors: Z Koporc; N Pilat; P Nierlich; P Blaha; S Bigenzahn; I Pree; E Selzer; M Sykes; F Muehlbacher; T Wekerle Journal: Am J Transplant Date: 2008-10 Impact factor: 8.086